Olaparib in People With Malignant Mesothelioma

Related Clinical Trial
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma Olaparib in Patients With HRD Malignant Mesothelioma αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors Intravenous Magnesium in Patients Receiving Cisplatin SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II Transitions Project High Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study 18F-FSPG PET/CT for Cancer Patients on Therapy Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso Molecular Analysis of Thoracic Malignancies A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion Pulmonary Interstitial Lymphography in Early Stage Lung Cancer Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Amatuximab for High Mesothelin Cancers αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies First-in-human Study of S-588210 (S-488210+S-488211) Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer Rapid Autopsy and Procurement of Cancer Tissue Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs Mithramycin for Lung, Esophagus, and Other Chest Cancers APG-2449 in Patients With Advanced Solid Tumors CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD) Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. Rehabilitation by Effort for Patients With Advanced Bronchial Cancer A Study of LY3023414 in Participants With Advanced Cancer Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen Dose Individualization of Pemetrexed – IMPROVE-III Dose Individualization of Pemetrexed – IMPROVE-II Dose Individualization of Pemetrexed – IMPROVE-I Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT) uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Gefitinib in Treating Patients With Malignant Mesothelioma DENdritic Cell Immunotherapy for Mesothelioma Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901) Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Sorafenib in Previously Treated Malignant Mesothelioma A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107 Capecitabine in Treating Patients With Malignant Mesothelioma A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma Olaparib in People With Malignant Mesothelioma CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma IP3R Modulation by Cancer Genes in Mesothelioma Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment SU5416 in Treating Patients With Malignant Mesothelioma Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Autologous Redirected RNA Meso-CIR T Cells Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Tomotherapy Treatment for Mesothelioma Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Mesothelioma and Radical Surgery 2 Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery Isolated Thoracic Perfusion (ITP-F) for MPM Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Serum Biomarkers in Diagnosis of Mesothelioma Short Neoadjuvant Hemithoracic IMRT for MPM Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma Nivolumab in Patients With Recurrent Malignant Mesothelioma Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Four Versus Six Cycles of Pemetrexed/Platinum for MPM A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Nintedanib (BIBF 1120) in Mesothelioma Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Vinorelbine in Mesothelioma Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma S0509 – AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Staging Procedures to Diagnose Malignant Pleural Mesothelioma Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Intrapleural Gene Transfer for Pleural Mesothelioma Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma Thromboelastography During Surgery for Malignant Pleural Mesothelioma Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma Combination Gene Transfer and Chemotherapy Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma The IMmunotherapy Pleural 5-ALA PDT Intrapleural Cryotherapy for Malignant Pleural Mesothelioma Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Dendritic Cell-based Immunotherapy in Mesothelioma MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Do Your Genes Put You at a Higher Risk of Developing Mesothelioma Trimodality Therapy for Malignant Pleural Mesothelioma Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma Dasatinib in Resectable Malignant Pleural Mesothelioma Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma ATREUS – Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma Pembrolizumab + Defactinib In Pleural Mesothelioma Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM) Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma Response Evaluation in Malignant Pleural Mesothelioma Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment

Brief Title

Olaparib in People With Malignant Mesothelioma

Official Title

Phase II Study of Olaparib in Subjects With Malignant Mesothelioma

Brief Summary

      Background:

      The drug olaparib may stop cancer cells from fixing damage to their DNA. It has been approved
      to treat certain cancers in people that were born with a mutation in the BRCA gene. It has
      not been approved for treating mesothelioma. But some people with mesothelioma have mutations
      in a gene, BAP1 related to BRCA. Researchers want to see if olaparib can work in patients
      with mutations in this gene. They also want to see if works on mutations in other genes or
      patients without any mutations. They want to see if olaparib causes mesothelioma tumors to
      shrink.

      Objective:

      To study the effect of olaparib on mesothelioma.

      Eligibility:

      People ages 18 and older with malignant mesothelioma that has already been treated

      Design:

      Participants will be screened with

      Sample of tumor tissue or fluid

      Medical history

      Physical exam

      Blood, heart, and urine tests

      Scans and x-rays

      Participants will give blood and tissue samples. These will be genetically tested.

      The study will be done in 21-day cycles.

      Participants will take tables of the study drug 2 times each day. They will get information
      on what food and drugs to avoid during the study. They will get information about birth
      control. They will keep a diary of doses and symptoms.

      Participants will have blood and urine tests and scans every few weeks.

      Participants will be told any important genetic testing results.

      Participants will stay in the study until their disease gets worse or the participant or
      their doctor chooses to stop it.

      About 30 days after stopping the study drug, participants will have a follow-up visit. They
      will have a medical history, physical exam, blood tests, and scans.

      Some participants will continue to have scans every 6 weeks.

      ...
    

Detailed Description

      Background:

        -  Malignant mesothelioma is an invasive and often fatal neoplasm that arises from
           mesothelium that lines several organs.

        -  Recent studies have identified germline mutations in the gene encoding BRCA1 associated
           protein-1 (BAP1) which can predispose to mesothelioma

        -  In addition to mesothelioma, germline BAP1 mutations confer increased susceptibility for
           the development of several other tumors including uveal melanoma, cutaneous melanoma,
           renal cell cancers and possibly other cancers

        -  In addition to BAP1, we found several novel germline variants that have previously not
           been associated with risk of developing mesothelioma.

        -  As evidenced by recent data derived from ovarian and prostate cancer patients, mutations
           in DNA repair genes can define subgroups of cancer patients with distinct
           vulnerabilities to DNA damage response inhibitors.

        -  Olaparib is a PARP inhibitor indicated as monotherapy in patients with deleterious or
           suspected deleterious germline BRCA mutated

        -  Both established and patient derived mesothelioma cell lines with mutated DNA repair
           genes are sensitive to olaparib.

      Objective:

      -Determine the efficacy with respect to objective response rate of olaparib in patients with
      malignant mesothelioma based on somatic or germline mutation status of DNA repair genes

      Eligibility:

        -  Patients must have progressive, histologically or cytologically confirmed malignant
           mesothelioma.

        -  Age greater than or equal to 18 years

        -  Patients must have received prior platinum and pemetrexed based therapies

        -  Adequate organ and bone marrow function

      Design:

        -  This is a phase II, single center study of olaparib in subjects with malignant
           mesothelioma

        -  All subjects will take olaparib by mouth twice daily until disease progression or
           intolerable side effects

        -  Subjects will be assessed for safety (continuously) and efficacy (every 6 weeks)

        -  Subjects will be analyzed in 3 separate comparison groups according to their mutation
           status

             -  Comparison Group 1: Patients with a germline mutation in DNA repair genes

             -  Comparison Group 2: Patients with BAP1 somatic mutations

             -  Comparison Group 3: Patients with neither germline mutations nor BAP 1 somatic
                mutations

        -  Up to 30 evaluable subjects will be enrolled
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

objective response rate


Condition

Mesothelioma

Intervention

Olaparib

Study Arms / Comparison Groups

 1/Olaparib
Description:  Twice daily oral olaparib

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

40

Start Date

July 11, 2018

Completion Date

December 31, 2020

Primary Completion Date

December 4, 2019

Eligibility Criteria

        -  INCLUSION CRITERIA:

          -  Patients must have histologically or cytologically malignant mesothelioma confirmed by
             the NCI Laboratory of Pathology. Patients with pleural, peritoneal, pericardial or
             tunica vaginalis mesothelioma are eligible.

          -  Archival tumor samples must be available and sufficient for diagnostic and genetic
             testing; if archival sample insufficient for testing, subject must have lesions
             amenable to biopsy and be willing to undergo biopsy.

          -  Patients must have measurable disease.

          -  Patients must have progressive disease at study entry

          -  Patients must have received prior platinum and pemetrexed based therapies. Response to
             platinum is not an eligibility criterion for enrollment.

          -  Age greater than or equal to 18 years. Because no dosing or adverse event data are
             currently available on the use of olaparib in patients <18 years of age, children are
             excluded from this study, but may be eligible for future pediatric trials.

          -  ECOG performance status less than or equal to 1.

          -  Patients must have a life expectancy of greater than or equal to 16 weeks

          -  Patients must have adequate organ and marrow function less than or equal to 5days
             prior to C1D1 as defined below:

               -  leukocytes greater than or equal to 3,000/mcL

               -  absolute neutrophil count greater than or equal to greater than or equal to
                  1,500/mcL without growth factor support

               -  platelets greater than or equal to 100,000/mcL

               -  hemoglobin greater than or equal to 10 g/dL with no blood transfusion in the past
                  28 days

               -  total bilirubin less than or equal to 1.5 x ULN (unless Gilbert s Disease)

               -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of
                  normal (less than or equal to 5X ULN in the presence of liver metastases)

               -  creatinine clearance greater than or equal to 51 mL/min (calculated using the
                  -Cockcroft-Gault formula.

          -  Pre-clinical data indicate that olaparib can have adverse effects on embryofetal
             survival and development. It is further not known whether olaparib or its metabolites
             are found in seminal fluid. For these reasons:

          -  Women of childbearing potential and their partners, who are sexually active, must
             agree to the use of 2 highly effective forms of contraception in combination (male
             condom plus one other method or must totally/truly abstain from any form of sexual
             intercourse. This should be started from the signing of the informed consent,
             throughout their participation in the study and for at least 1 month after the last
             dose of olaparib.

          -  Male patients must use a condom during treatment and for 3 months after the last dose
             of olaparib when having sexual intercourse with a pregnant woman or with a woman of
             childbearing potential. Female partners of male patients should also use a highly
             effective form of contraception if they are of childbearing potential. Male patients
             should not donate sperm throughout the period of taking olaparib and for 3 months
             following the last dose of olaparib.

          -  Acceptable birth control methods:

               -  Total sexual abstinence i.e., refrain from any form of sexual intercourse in line
                  with the patients usual and/or preferred lifestyle. Abstinence must be for the
                  total duration of the study treatment and for at least 1month (for female
                  patients) or 3 months (for male patients) after the last dose of study treatment.
                  Periodic abstinence (e.g., calendar ovulation, symptothermal, post-ovulation
                  methods) and withdrawal are not acceptable methods of contraception.

               -  Vasectomised sexual partner PLUS male condom. With participant assurance that
                  partner received post-vasectomy confirmation of azoospermia.

               -  Tubal occlusion PLUS male condom

               -  Intrauterine Device PLUS male condom. Provided coils are copper-banded.

               -  Etonogestrel implants (e.g., Implanon , Norplant ) PLUS male condom

               -  Normal and low dose combined oral pills PLUS male condom

               -  Hormonal shot or injection (e.g., Depo-Provera) PLUS male condom

               -  Intrauterine system device (e.g., levonorgestrel-releasing intrauterine system
                  -Mirena ) PLUS male condom

               -  Norelgestromin/ethinyl estradiol transdermal system PLUS male condom

               -  Intravaginal device (e.g., ethinyl estradiol and etonogestrel) PLUS male condom

               -  Cerazette (desogestrel) PLUS male condom. Cerazette is currently the only highly
                  efficacious progesterone based pill.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents.

          -  Patients who have received any previous treatment with a PARP inhibitor, including
             olaparib.

          -  Patients receiving any systemic chemotherapy or radiotherapy (except for palliative
             reasons) within 3 weeks prior to study treatment

          -  Patients with other malignancy documented as occurring within the last 1 year except:
             adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the
             cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or
             other solid tumors includinglymphomas (without bone marrow involvement) documented as
             curatively treated or under control for greater than or equal to 1 year.

          -  Patients with features suggestive of MDS/AML on peripheral blood smear.

          -  Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence
             of brain metastases is not required. The patient can receive a stable dose of
             corticosteroids before and during the study as long as these were started at least 4
             weeks prior to treatment. Patients with spinal cord compression unless considered to
             have received definitive treatment for this and evidence of clinically stable disease
             for 28 days.

          -  History of allergic reactions or hypersensitivity attributed to compounds of similar
             chemical or biologic composition to olaparib or its excipients.

          -  Patients who have had a whole blood transfusion within 120 days prior to enrollment.
             (Packed red blood cells and platelet transfusions are acceptable)

          -  Patients with persistent toxicities (greater than or equal to CTCAE grade 2) with the
             exception of alopecia,caused by previous cancer therapy

          -  Concomitant use of known strong or moderate CYP3A inhibitors (e.g. itraconazole,
             telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or
             cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate
             CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole,
             verapamil). The required washout period prior to starting olaparib is 2 weeks.

          -  Concomitant use of known strong CYP3A inducers (e.g. phenobarbital, enzalutamide,
             phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John s
             Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required
             washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital
             and 3 weeks for other agents.

          -  Resting ECG with QTcF > 470 msec on 2 or more time points within a 24-hour period or
             family history of long QT syndrome

          -  Patients that have had major surgery within 2 weeks of starting study treatment and
             patients must have recovered from any effects of any major surgery.

          -  Patients unable to swallow orally administered medication and patients with
             gastrointestinal disorders likely to interfere with absorption of the study
             medication.

          -  Patients considered a poor medical risk due to a serious, uncontrolled medical
             disorder, non-malignant systemic disease or active, uncontrolled infection. Examples
             include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3
             months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal
             cord compression, superior vena cava syndrome, extensive interstitial bilateral lung
             disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder
             that prohibits obtaining informed consent.

          -  Pregnant women are excluded from this study because olaparib has the potential for
             teratogenic or abortifacient effects. Women must either be post-menopausal or must
             have a negative pregnancy test (urine or serum) less than or equal to 28 days prior to
             enrollment and confirmed on day 1 of cycle 1 of study therapy. Postmenopausal is
             defined as:

        Amenorrheic for 1 year or more following cessation of exogenous hormonaltreatments

        Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the
        post-menopausal range for women under 50 years of age

        radiation-induced oophorectomy with last menses >1 year ago

        chemotherapy-induced menopause with >1-year interval since last menses

        surgical sterilisation (bilateral oophorectomy or hysterectomy)

          -  Because there is an unknown but potential risk for adverse events in nursing infants
             secondary to treatment of the mother with olaparib, breastfeeding should be
             discontinued if the mother is treated with olaparib.

          -  Immunocompromised patients are excluded.

          -  Patients who are known to be serologically positive for human immunodeficiency virus
             (HIV). This includes HIV patients on antiretroviral therapy due to the potential for
             pharmacokinetic interactions with olaparib.

          -  Patients with known active hepatitis (i.e. Hepatitis B or C) due to risk of
             transmitting the infection through blood or other body fluids

          -  Previous allogeneic hematopoietic stem cell transplant, allogeneic bone marrow
             transplant or double umbilical cord blood transplant (duCBT)
      

Gender

All

Ages

18 Years - 99 Years

Accepts Healthy Volunteers

No

Contacts

Raffit Hassan, M.D., (240) 858-3159, [email protected]

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03531840

Organization ID

180097

Secondary IDs

18-C-0097

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Raffit Hassan, M.D., Principal Investigator, National Cancer Institute (NCI)


Verification Date

July 14, 2020